NASDAQ:OCGNOcugen Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ocugen Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.28 0.00 (0.00 %) (As of 04/5/2020 03:53 AM ET) Add Compare Share Today's Range$0.28Now: $0.28▼$0.2950-Day Range$0.26MA: $0.41▼$0.5752-Week Range$0.24Now: $0.28▼$21.60Volume943,592 shsAverage Volume1.54 million shsMarket Capitalization$4.48 millionP/E RatioN/ADividend YieldN/ABeta2.42 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingOcugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.63, Ocugen has a potential upside of 480.4% from its current price of $0.28.Amount of Analyst CoverageOcugen has only been the subject of 1 research reports in the past 90 days. Previous Next 3.4 Community Rank Outperform VotesOcugen has received 48 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOcugen has received 23 “underperform” votes. (Add your “underperform” vote.)Community SentimentOcugen has received 67.61% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ocugen and other stocks. Vote “Outperform” if you believe OCGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OCGN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOcugen does not currently pay a dividend.Dividend GrowthOcugen does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ocugen insiders have not sold or bought any company stock.Percentage Held by Insiders44.70% of the stock of Ocugen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.12% of the stock of Ocugen is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ocugen are expected to decrease by -31.58% in the coming year, from ($0.19) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocugen is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocugen is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.58 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OCGN Previous Symbol CUSIPN/A CIKN/A Webhttp://ocugen.com/ Phone484-328-4701Debt Debt-to-Equity Ratio0.10 Current Ratio3.47 Quick Ratio0.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.44) per share Price / Book-0.64Profitability EPS (Most Recent Fiscal Year)($1.48) Net Income$-20,240,000.00 Net MarginsN/A Return on Equity-78.71% Return on Assets22.00%Miscellaneous Employees14 Outstanding Shares16,000,000Market Cap$4.48 million Next Earnings Date5/20/2020 (Estimated) OptionableNot Optionable Receive OCGN News and Ratings via Email Sign-up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:OCGN Rates by TradingView Ocugen (NASDAQ:OCGN) Frequently Asked Questions How has Ocugen's stock been impacted by COVID-19 (Coronavirus)? Ocugen's stock was trading at $0.3612 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OCGN stock has decreased by 22.5% and is now trading at $0.28. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Ocugen? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ocugen. When is Ocugen's next earnings date? Ocugen is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Ocugen. What price target have analysts set for OCGN? 2 equities research analysts have issued 1 year price targets for Ocugen's shares. Their forecasts range from $1.25 to $2.00. On average, they anticipate Ocugen's stock price to reach $1.63 in the next twelve months. This suggests a possible upside of 480.4% from the stock's current price. View analysts' price targets for Ocugen. Has Ocugen been receiving favorable news coverage? Media headlines about OCGN stock have trended very negative recently, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ocugen earned a news impact score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutOcugen. Are investors shorting Ocugen? Ocugen saw a drop in short interest in March. As of March 13th, there was short interest totaling 676,700 shares, a drop of 11.0% from the February 27th total of 760,500 shares. Based on an average daily volume of 1,998,500 shares, the short-interest ratio is presently 0.3 days. Approximately 1.4% of the shares of the company are sold short. View Ocugen's Current Options Chain. Who are some of Ocugen's key competitors? Some companies that are related to Ocugen include NanoVibronix (NAOV), Bionik Laboratories (BNKL), Rewalk Robotics (RWLK), Precision Therapeutics (POAI) and Avitar (AVTI). What other stocks do shareholders of Ocugen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ocugen investors own include Onconova Therapeutics (ONTX), Ibio (IBIO), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), Opko Health (OPK), FuelCell Energy (FCEL), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), Co-Diagnostics (CODX) and Sierra Oncology (SRRA). Who are Ocugen's key executives? Ocugen's management team includes the following people: Dr. Shankar Musunuri Ph.D., MBA, Founder, Chairman & CEODr. Uday B. Kompella, Founder & DirectorDr. Rasappa Arumugham, Chief Scientific OfficerMs. Kelly A. Beck M.B.A., P.M.P., SPHR, VP of Investor Relations & Admin.Dr. Daniel M. Jorgensen M.D., MPH, MBA, Chief Medical Officer What is Ocugen's stock symbol? Ocugen trades on the NASDAQ under the ticker symbol "OCGN." How do I buy shares of Ocugen? Shares of OCGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ocugen's stock price today? One share of OCGN stock can currently be purchased for approximately $0.28. How big of a company is Ocugen? Ocugen has a market capitalization of $4.48 million. The company earns $-20,240,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. Ocugen employs 14 workers across the globe. View additional information about Ocugen. What is Ocugen's official website? The official website for Ocugen is http://ocugen.com/. How can I contact Ocugen? Ocugen's mailing address is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. The company can be reached via phone at 484-328-4701 or via email at [email protected] This page was last updated on 4/5/2020 by MarketBeat.com StaffFeatured Article: What are the benefits of a balanced fund?
